After surging 119.70% so far in April, Organon & Co. (NYSE:OGN) secures a spot on our list of the mid-cap stocks with the highest gains in April.
A well-stocked pharmacy shelf full of the company’s pharmaceuticals, nutraceuticals, over-the-counter medications, and health care products.
On April 26, 2026, Sun Pharmaceutical Industries confirmed that it would acquire Organon & Co. (NYSE:OGN), a U.S. drugmaker, in an all-cash transaction with an estimated value of $11.75 billion, including debt. This acquisition marks the largest overseas acquisition by an Indian pharmaceutical company. The closing is anticipated to occur in early 2027, and Sun Pharma, India’s largest pharmaceutical company by market value ($40 billion), will pay $14.00 per share, a premium of over 24% to Organon’s April 24 closing price.
The strategic rationale is readily apparent: Sun is expanding its focus to higher-margin specialty drugs in obesity, oncology, and dermatology in order to overcome the decline in U.S. generic sales, which are further impacted by changing tariff regulations.
With $6.2 billion in sales at 30% EBITDA margins, Sun’s revenue and EBITDA will double as a result of the acquisition. Furthermore, Nuvama Wealth Management’s analyst Shrikant Akolkar projects that by FY28, it will be 30%–40% EPS accretive.
The main overhang is Organon & Co. (NYSE:OGN)’s net debt of over $8.6 billion. However, with Sun’s solid balance sheet and dedicated bank financing, Akolkar anticipates that the concerns will subside by year three. Beyond financial gains, Sun gains entry into biosimilars, a portfolio of more than 70 general and women’s health medications in almost 140 countries, and significant access to China, Brazil, and other emerging markets where its presence has been restricted.
Sun Pharma’s shares rose 7%, while Organon & Co. (NYSE:OGN)’s shares surged 16% in premarket trade.
On April 28, 2026, Piper Sandler upgraded Organon & Co. (NYSE:OGN) from “Underweight” to “Neutral” with a $14 price target. The firm highlighted the transaction as “lightning in a bottle” and acknowledged that it was surprising that a buyer showed up, given its assessment of Organon’s asset quality. Citing the early 2027 close, BofA concurrently changed its rating to No Rating, stating that shares are no longer trading on fundamentals.
Organon & Co. (NYSE:OGN) is a global healthcare company spun off from Merck in 2021, focused on women’s health, biosimilars, and established medicines. It is based in New Jersey and operates in over 140 countries.
While we acknowledge the risk and potential of OGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than OGN and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center